Celularity Inc.

About Celularity Inc.

Celularity Inc. is a biotechnology company focused on leading the next evolution in cellular medicine by developing and commercializing off-the-shelf allogeneic cellular therapies derived from the postpartum placenta. Their mission is to deliver therapies at unparalleled scale, quality, and economics, targeting aging-related diseases, cancer, immune disorders, and degenerative diseases, while harnessing the unique biology and availability of the placenta to address significant unmet global needs for accessible and affordable treatments.

Products & Services

NK Cell Platform:Allogeneic, cryopreserved natural killer (NK) cells, including genetically modified and unmodified versions, targeting various diseases.

T Cell Platform:Engineered T cells, including CAR T-cells, for therapeutic applications in cancer and other conditions.

Mesenchymal-like Adherent Stromal Cells (MLASCs):Cells derived from the placenta used in therapies for degenerative and aging-related diseases.

Exosomes:Placental-derived exosomes as part of their innovative therapeutic solutions.

Advanced Biomaterials:Biomaterial products derived from the placenta for medical applications.

Mesenchymal-like adherent stromal cells (MLASCs)

Natural Killer (NK) Cells

T Cells

Advanced biomaterial products

Exosomes

Specialties

Allogeneic Cellular Therapies Placental-Derived Cell Therapies NK Cell Therapies CAR T-Cell Therapies Mesenchymal-like Adherent Stromal Cells (MLASCs) Advanced Biomaterials Regenerative Medicine Allogeneic cellular therapies Placenta-derived regenerative medicine Cellular medicine manufacturing Biomaterials

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Other T: - FT: Other	A: 12200000 MR: - FA: $12.2 Million FAN: 12200000	D: 2026-02-10 FD: 2026-02-10	1 investors
2	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: $10.00 million FAN: 10000000	D: 2025-12-22 FD: 2025-12-22	1 investors
3	RT: Debt T: - FT: Debt	A: 12000000 MR: - FA: up to $12 Million FAN: 12000000	D: 2025-12-18 FD: 2025-12-18	1 investors
4	RT: Mixed (Private Placement and Senior Secured Loan) T: - FT: Mixed (Private Placement and Senior Secured Loan)	A: 21000000 MR: - FA: $21 million FAN: 21000000	D: 2024-01-16 FD: 2024-01-16	2 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: approximately $3 million FAN: 3000000	D: 2023-07-27 FD: 2023-07-27	1 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6000000 MR: - FA: approximately $6 million FAN: 6000000	D: 2023-04-05 FD: 2023-04-05	1 investors

Other Latest

2026-02-10

$12.2M

1 investor (Pro only)

Debt 2025-12-22

$10.0M

Debt 2025-12-18

$12.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert J. Hariri

Chairperson, Founder, and CEO

A

Anna Gosiewska

R&D, Degenerative Diseases

S

Sharmila Koppisetti

Clinical Development Immunology & Drug Safety

T

Tim Wilk

Technical Operations

R

Robert J. Hariri

Chairperson, Founder & CEO

P

Peter Diamandis

Director

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Celularity Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised